Equities

Xylo Technologies Ltd

Xylo Technologies Ltd

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.68
  • Today's Change-0.195 / -10.43%
  • Shares traded14.05k
  • 1 Year change-65.10%
  • Beta1.5048
Data delayed at least 15 minutes, as of Jun 07 2024 20:55 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xylo Technologies Ltd, formerly known ad Medigus Ltd, is an Israel-based medical device company specializing in developing minimally invasive endosurgical tools and imaging solutions across medical and industrial applications. The Company developed a range of micro video cameras under micro ScoutCam portfolio of products and the Medigus Ultrasonic Surgical Endostapler, or MUSE system endoscopic device for the treatment of gastroesophageal reflux disease (GERD).

  • Revenue in USD (TTM)91.72m
  • Net income in USD-16.03m
  • Incorporated1999
  • Employees84.00
  • Location
    Xylo Technologies Ltd10 HaNechoshet StreetTEL AVIV-YAFO 6971072IsraelISR
  • Phone+972 36899124
  • Fax+972 86466770
  • Websitehttps://medigus.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aptevo Therapeutics Inc0.00-27.31m3.28m40.00--0.0916-----98.49-97.900.009.060.00----0.00-103.85-47.16-134.86-85.03-------583.47----0.00---100.00---365.90------
Altamira Therapeutics Ltd118.07k-8.14m3.32m10.00--0.3045--28.27-31.58-26.660.24034.890.015134.0532.3011,806.78-103.88-73.80-6,364.67-123.19-87.90---6,892.99--1.38-4.360.0152------61.02------
NovaBay Pharmaceuticals Inc14.23m-18.43m3.32m24.00------0.229-108.80-108.9750.490.17491.412.9111.08593,041.70-108.92-61.51-185.74-83.8954.4759.99-77.22-86.470.7462--0.8629--2.243.32-2.66---15.46--
TRACON Pharmaceuticals Inc12.15m1.75m3.35m17.001.87--1.850.26910.65090.65096.27-0.66181.37----714,411.8019.78-79.42---177.85----14.39-813.81---0.4613------32.0587.68------
Manuka Inc671.00k-1.14m3.36m4.00------5.01-0.0128-0.01280.0066-0.01242.410.941237.28167,750.00-410.43-463.75----88.08---170.04-732.150.0194-----------854.23------
Gold River Productions Inc.-100.00bn-100.00bn3.38m1.00k--5.09----------0.0005----------------------------0.00-------100.11------
Clearmind Medicine Inc0.00-8.09m3.39m----0.6727-----30.92-30.920.001.590.00-------109.55-218.20-180.61-488.96-----------2.900.0184-------25.03------
Eiger Biopharmaceuticals Inc15.77m-74.96m3.41m25.00------0.2263-50.80-50.8010.69-9.770.19850.00649.19630,920.00-94.31-60.25-186.10-76.5199.91---475.26-823.590.6809-22.031.54--16.98--22.54--10.51--
Atreca Inc0.00-97.76m3.41m90.00--0.3368-----2.49-2.490.000.27150.00----0.00-98.54-44.99-116.19-48.05------------0.00------11.13---8.46--
Avenue Therapeutics Inc0.00-7.18m3.53m3.00--0.7929-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
Petros Pharmaceuticals Inc4.69m-20.46m3.55m21.00--0.3221--0.6831-7.37-7.371.681.550.15420.78582.15223,487.10-29.37-32.43-41.80-68.0569.9162.04-190.50-201.701.46--0.4284---2.83-16.1531.06------
Biostax Corp0.00-1.57m3.56m-----------0.0188-0.01880.00-0.0580.00-------390.77-81.51---------------6.05--------53.32------
Xylo Technologies Ltd - ADR91.72m-16.03m3.58m84.00--0.1409--0.0368-9.52-9.5254.4012.631.1438.255.431,091,952.00-26.90---61.87--12.91---23.69--1.00-1.450.2318---0.1459---63.27------
Mosaic Immunoengineering Inc0.00-897.69k3.62m3.00---------0.1245-0.12450.00-0.84980.00----0.00-789.46-----------------26.91--------57.65------
60 Degrees Pharmaceuticals Inc378.20k-1.07m3.63m2.00------9.23-0.1563-0.15630.05640.61210.04740.88271.90126,066.70-9.87-------23.45---208.43--6.77--0.0217---50.40--35.51------
Sentient Brands Holdings Inc0.00-818.63k3.86m2.00---------0.0145-0.01450.00-0.0360.000.0188--0.00-317.87-220.36------41.81---31,451.190.0354-2.27-----73.68--34.98------
Data as of Jun 07 2024. Currency figures normalised to Xylo Technologies Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.24%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley & Co. LLCas of 31 Mar 20241.70k0.10%
RhumbLine Advisers LPas of 31 Mar 20241.44k0.09%
Woodbury Financial Services, Inc.as of 31 Dec 2023316.000.02%
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024316.000.02%
UBS Securities LLCas of 31 Mar 2024181.000.01%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 202421.000.00%
Global Wealth Strategies & Associates LLCas of 31 Mar 20246.000.00%
JPMorgan Asset Management (Europe) SARL (Germany)as of 31 Mar 20240.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.